Browse evidence-based analysis of health-related claims and assertions
For Japanese adults with type 2 diabetes on sitagliptin, ipragliflozin improves insulin resistance more than metformin, which doesn't change insulin resistance levels, with a clear difference between the two treatments.
For Japanese adults with type 2 diabetes on sitagliptin, ipragliflozin lowers insulin levels significantly more than metformin, which actually slightly raises insulin levels, with a clear difference between the two treatments.
For Japanese adults with type 2 diabetes on sitagliptin, ipragliflozin boosts good cholesterol more than metformin after 24 weeks, with a noticeable difference in how much HDL levels rise.
For Japanese adults with type 2 diabetes on sitagliptin, metformin reduces bad cholesterol more than ipragliflozin, which actually raises bad cholesterol levels, with a clear difference between the two treatments.
For Japanese adults with type 2 diabetes on sitagliptin, metformin lowers blood sugar more effectively than ipragliflozin after 24 weeks, with a clear difference in how much HbA1c drops.
When Japanese adults with type 2 diabetes take sitagliptin plus ipragliflozin for 24 weeks, their outer fat layer shrinks, but those taking metformin gain outer fat, with a clear difference between the two treatments.
For Japanese adults with type 2 diabetes taking sitagliptin, taking ipragliflozin for 24 weeks makes belly fat inside the body decrease more than taking metformin, with a noticeable difference in fat loss.
When analyzing gene activity patterns in fat tissue during weight loss, scientists found that liver X receptor alpha might control how adiponectin receptors work, which could affect metabolism.
Whether obese women eat a low-fat or high-fat diet while cutting calories, their fat tissue genes respond the same way, so the type of fat in the diet doesn't change how these genes work during weight loss.
When obese women lose weight on a low-calorie diet, the activity of the PPARγ gene in fat tissue goes down, which affects how fat cells develop and store fat.
Obese women following a low-calorie diet for 10 weeks show reduced activity of the uncoupling protein 2 gene in their fat tissue, which affects how cells produce energy.
When obese women lose weight on a low-calorie diet, the activity of the lipoprotein lipase gene in fat tissue goes down, which affects how fats are stored in cells.
Obese women on a low-calorie diet for 10 weeks show reduced activity of the CD36 gene in their fat tissue, which affects how fatty acids are taken up by cells.
When obese women follow a low-calorie diet for 10 weeks, the activity of the natriuretic peptide receptor gene in fat tissue decreases, which affects how fat cells respond to certain hormones.
Obese women on a low-calorie diet for 10 weeks show reduced activity of the hormone-sensitive lipase gene in their fat tissue, which affects how fat is broken down.
When obese women lose weight on a low-calorie diet, the activity of the phosphodiesterase 3B gene in fat tissue goes down, which affects how fat cells respond to insulin.
Obese women following a low-calorie diet for 10 weeks show reduced activity of the osteonectin gene in their fat tissue, which is involved in tissue structure and fat storage.
Obese women on a low-calorie diet for 10 weeks show reduced activity of the leptin gene in their fat tissue, which is linked to hunger regulation.
When obese women follow a low-calorie diet for 10 weeks, the activity of the PGC-1α gene in their fat tissue increases, which helps regulate energy use in cells.
Chitosan doesn't lead to meaningful weight loss in overweight or obese adults over 24 weeks.
Chitosan didn't affect other health measures like body fat, blood pressure, or quality of life compared to a placebo.
A hormone treatment called tesamorelin slightly raises long-term blood sugar levels by 0.19% more than a placebo in people with HIV after six months of treatment.
Chitosan might cause small changes in cholesterol and blood sugar levels, but the study didn't say if they went up or down.
A hormone treatment called tesamorelin raises IGF-1 hormone levels more than a placebo in people with HIV at 2 weeks, 3 months, and 6 months of treatment.